1. Home
  2. CRS vs MRNA Comparison

CRS vs MRNA Comparison

Compare CRS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carpenter Technology Corporation

CRS

Carpenter Technology Corporation

HOLD

Current Price

$559.49

Market Cap

21.3B

Sector

Industrials

ML Signal

HOLD

Logo Moderna Inc.

MRNA

Moderna Inc.

HOLD

Current Price

$49.88

Market Cap

21.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRS
MRNA
Founded
1910
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.3B
21.6B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
CRS
MRNA
Price
$559.49
$49.88
Analyst Decision
Strong Buy
Hold
Analyst Count
8
12
Target Price
$419.75
$34.27
AVG Volume (30 Days)
562.9K
5.1M
Earning Date
04-29-2026
05-01-2026
Dividend Yield
0.20%
N/A
EPS Growth
100.54
21.77
EPS
7.29
N/A
Revenue
$2,157,700,000.00
$19,263,000,000.00
Revenue This Year
$9.21
$9.36
Revenue Next Year
$10.50
$15.43
P/E Ratio
$71.75
N/A
Revenue Growth
20.03
4.29
52 Week Low
$228.00
$22.28
52 Week High
$537.41
$59.55

Technical Indicators

Market Signals
Indicator
CRS
MRNA
Relative Strength Index (RSI) 80.49 53.49
Support Level $297.11 $45.09
Resistance Level N/A $54.50
Average True Range (ATR) 19.36 2.83
MACD 8.35 0.19
Stochastic Oscillator 99.61 74.13

Price Performance

Historical Comparison
CRS
MRNA

About CRS Carpenter Technology Corporation

Carpenter Technology Corp supplies specialty metals to a variety of end markets, including aerospace and defense, industrial machinery and consumer durables, medical, and energy, among others. The company's reportable segments include; Specialty Alloys Operations and Performance Engineered Products. It generates maximum revenue from the Specialty Alloys Operations segment. The SAO segment is comprised of the company's alloy and stainless steel manufacturing operations. This includes operations performed at mills predominantly in Reading and Latrobe, Pennsylvania, and surrounding areas as well as South Carolina and Alabama. Geographically, the company derives its maximum revenue from the United States and the rest from Europe, Asia Pacific, Mexico, Canada, and other regions.

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Share on Social Networks: